Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
| June 22, 2021 | June 2021 Bond Updates |
|
OSLO, Norway, June 22, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces encouraging initial results from the LYMRIT 37-05 Phase 1 trial investigating Betalutin® (177Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)... |
| View more at: https://www.prnewswire.com:443/news-releases/nordic-nanovector-announces-initial-results-from-lymrit-37-05-phase-1-trial-of-betalutin-in-relapsedrefractory-diffuse-large-b-cell-lymphoma-dlbcl-301316962.html |
| Related News |